Responsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia

Basit Öğe Kaydı
dc.contributor.authorAkın, Mehmet
dc.contributor.authorAtay, Enver
dc.contributor.authorÖztekin, Osman
dc.contributor.authorKaradeniz, Cem
dc.contributor.authorKarakus, Yasin Tuğrul
dc.contributor.authorYılmaz, Bilal
dc.contributor.authorErdoğan, Fırat
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:02:27Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:02:27Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000331063500007
dc.descriptionPubMed ID: 24087940
dc.description.abstractIntravenous (IV) ferric iron (Fe)-carbohydrate complexes are used for treating Fe deficiency in children with iron-refractory iron-deficiency anemia (IRIDA). An optimal treatment has yet to be determined. There are relatively little publications on the responsiveness to IV iron therapy in children with IRIDA. Patients and Method: This study analyzed responses to IV iron sucrose therapy given to 11 children, ranging in age from 2 to 13 years (mean 4.8 years), with iron-deficiency anemia who were unresponsive to oral iron therapy. Results: The hemoglobin and ferritin values (mean) of the 11 children with IRIDA were 7.7 g/dL and 4.8 ng/mL at diagnosis. Both hemoglobin and ferritin levels increased to 9.5 g/dL, and 24 ng/mL, respectively, at 6 weeks after the first therapy. Although the level of hemoglobin was steady at 6 months after the first, and 6 weeks after the second therapy, the ferritin levels continued to increase up to 30 ng/mL and 47 ng/mL at 6 months after the first and 6 weeks after the second therapy, respectively. Conclusion: We recommend that IRIDA should be considered in patients presenting with iron-deficiency anemia of unknown cause that is unresponsive to oral iron therapy. Our results suggest that IV iron therapy should be administered only once in cases of IRIDA. Continued administration of IV iron would be of no benefit to increase hemoglobin levels. On the contrary, ferritin levels may continue to increase resulting in untoward effects of hyperferritinemia.
dc.identifier.citationAkın, M., Atay, E., Öztekin, O., Karadeniz, C., Karakus, Y. T. Yılmaz, B. ... Erdoğan, F. (2014). Responsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia. Pediatric Hematology and Oncology, 31(1), 57-61. https://dx.doi.org/10.3109/08880018.2013.829540
dc.identifier.doi10.3109/08880018.2013.829540
dc.identifier.endpage61
dc.identifier.issn0888-0018
dc.identifier.issn1521-0669
dc.identifier.issue1
dc.identifier.scopusqualityQ2
dc.identifier.startpage57
dc.identifier.urihttps://dx.doi.org/10.3109/08880018.2013.829540
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3651
dc.identifier.volume31
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAnemia
dc.subjectIRIDA
dc.subjectIron
dc.titleResponsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Atay, Enver-2014.pdf
Boyut:
89.97 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu